Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph early_phase_1
1
33%
Ph phase_1
1
33%
Ph not_applicable
1
33%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Not yet recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (33.3%)
Phase 11 (33.3%)
N/A1 (33.3%)

Trials by Status

not_yet_recruiting267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingnot_applicable

The Effect of Serum Ferritin in irAE

NCT06702566
not_yet_recruitingphase_1

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

NCT06364787
not_yet_recruitingearly_phase_1

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

NCT06364800

Clinical Trials (3)

Showing 3 of 3 trials
NCT06702566Not Applicable

The Effect of Serum Ferritin in irAE

Recruiting
NCT06364787Phase 1

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Not Yet Recruiting
NCT06364800Early Phase 1

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3